What the studies show
The most consistent finding is a heavy psychiatric burden, much of it predating any treatment. In Finland, 45.7% of gender-referred youth had needed specialist mental health care before referral, against 15.0% of matched peers (Ruuska et al., 2026); in English primary care, 52.7% had a record of anxiety, depression or self-harm (Jarvis et al., 2025). National registries agree that suicide and death rates are elevated: about 3.5 times the suicide rate and 7.7 times the rate of hospital-treated attempts in Denmark (Erlangsen et al., 2023), roughly twice the all-cause death rate in Sweden (Clark et al., 2026), and about 4 times the suicide rate in Taiwan, falling to 2.6 times against non-trans siblings (Hsu et al., 2025). Suicide nonetheless remains rare in absolute terms (0.03% of England's youth gender clinic patients; Biggs, 2022). In Finland, the excess suicide risk shrank and could be chance once psychiatric treatment history was accounted for (Ruuska et al., 2024).
Evidence that medical transition reduces this burden is weak. Systematic reviews rate mental health outcomes of puberty blockers and cross-sex hormones as very low certainty (Miroshnychenko et al., 2025) or low certainty, with no conclusion possible on suicide (Baker et al., 2021). Blocker cohorts in England and the US found no measurable change in distress or depression (Carmichael et al., 2021; Olson-Kennedy et al., 2025). A widely cited Swedish surgery study was corrected after a surgery versus no-surgery comparison of 1,018 people each showed no advantage (Bränström & Pachankis, 2020). In Finland, specialist psychiatric care among youth who transitioned rose from 9.8% to 60.7% (feminizing) and from 21.6% to 54.5% (masculinizing) after referral (Ruuska et al., 2026), and in Amsterdam suicides occurred at every stage, including 16 after completed surgery (Wiepjes et al., 2020). Links between chosen-name use or family acceptance and better mental health come from small cross-sectional surveys (Russell et al., 2018; Ryan et al., 2010), and a review found neither benefit nor harm of social transition established (Hall et al., 2024).
Limits of the evidence
Registry studies are large but adjust for little beyond age and sex, rarely record hormone or surgery exposure, and often rest on few suicides (12 in Denmark; 10 in Dhejne et al., 2011). Authors' explanations, whether minority stress or pre-existing mental illness, go untested. Treatment studies lack untreated comparison groups and lose many participants, so causal effects in either direction remain unresolved.